<DOC>
	<DOCNO>NCT01062399</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high energy x-ray kill tumor cell . Giving everolimus together temozolomide radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose everolimus give together temozolomide radiation therapy see well work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Everolimus , Temozolomide , Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - To define maximum tolerate dose everolimus ( establish dose 10 mg/day ) combine concurrent radiotherapy temozolomide patient newly diagnose glioblastoma multiforme . ( Phase I ) - To determine efficacy everolimus combination radiotherapy temozolomide follow adjuvant everolimus combination temozolomide , measure progression-free survival , patient . ( Phase II ) Secondary - To characterize safety profile everolimus combination radiotherapy temozolomide patient . ( Phase I ) - To determine overall survival patient . ( Phase II ) - To evaluate safety profile everolimus combination radiotherapy temozolomide patient . ( Phase II ) - To determine activation Akt/mTOR axis predict response everolimus . ( Phase II ) - To determine association tumor MGMT gene methylation status response everolimus . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study everolimus follow phase II , randomize study . - Phase I ( close accrual 7/3/12 ) : Patients undergo radiotherapy ( intensity-modulated 3-dimensional conformal radiotherapy ) 5 day week 6 week receive oral everolimus oral temozolomide daily 6 week . Beginning 28 day completion therapy , patient receive adjuvant oral everolimus daily day 1-28 oral temozolomide daily day 1-5 . Treatment adjuvant everolimus temozolomide repeat every 28 day 12 course absence disease progression unacceptable toxicity . - Phase II ( open accrual 12/19/12 ) : Patients stratify accord recursive partitioning analysis class ( III vs IV v V ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy ( intensity-modulated 3-dimensional conformal radiotherapy ) 5 day week 6 week receive oral temozolomide daily 6 week . Beginning 28 day completion therapy , patient receive adjuvant oral temozolomide daily day 1-5 . Treatment adjuvant temozolomide repeat every 28 day 12 course absence disease progression unacceptable toxicity . - Arm II : Patients receive treatment phase I. Tumor tissue , plasma , urine sample may collect correlative laboratory study ( mandatory phase II ) . After completion study treatment , patient follow every 3 month 1 year , every 4 month 1 year , every 6 month thereafter .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme ( GBM ) ( WHO grade IV ) central pathology review Gliosarcoma allow Tumor must supratentorial component Diagnosis must make surgical excision , either partial complete excision , within past 5 week Stereotactic biopsy Cavitron ultrasonic aspiratorderived tissue allow Tumor tissue available correlative study ( phase II ) Patients must ≥ 1 block tissue ; block submit , two tissue specimen punch skin punch ( 2 mm diameter ) tissue block contain tumor may submit No recurrent multifocal malignant glioma No metastasis detect tentorium beyond cranial vault PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % ANC ≥ 1,800/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL ( transfusion intervention allow ) PT/INR ≤ 1.5 BUN ≤ 30 mg/dL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time normal ALT AST ≤ 2.5 time normal Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fast triglyceride ≤ 2.5 time ULN ( one threshold exceed , patient eligible initiation appropriate lipidlowering medication ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ breast , oral cavity , cervix No severe , active comorbidity , define follow : NYHA class IIIIV symptomatic congestive heart failure Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within past 6 month , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease Severely impaired lung function , define spirometry DLCO 50 % normal predict value and/or oxygen saturation ≤ 88 % rest room air Uncontrolled diabetes , define fast serum glucose &gt; 1.5 time ULN Active ( acute chronic ) uncontrolled severe infection require IV antibiotic Liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis AIDS base upon current Centers Disease Control Prevention definition know HIV seropositivity ( HIV test require study entry ) Active connective tissue disorder lupus erythematosus scleroderma , opinion treat physician , may put patient high risk radiation toxicity Other major medical illness psychiatric impairment , investigator 's opinion , prevent administration completion study treatment No impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) No history deep vein thrombosis pulmonary embolism No prior allergic reaction temozolomide No known hypersensitivity mTOR inhibitor ( e.g. , sirolimus , temsirolimus , everolimus ) excipients PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered effect surgery , postoperative infection , complications No prior temozolomide No prior mTOR inhibitor ( e.g. , sirolimus , temsirolimus , everolimus ) No prior Gliadel wafer intratumoral intracavitary treatment No prior radiotherapy head neck ( except T1 glottic cancer ) result overlap radiotherapy field No prior chemotherapy radiosensitizers cancer head neck region Prior chemotherapy different cancer allow No prior radiotherapy chemotherapy GBM No prior concurrent treatment therapeutic clinical study At least 14 day since prior concurrent enzymeinducing antiepileptic drug Concurrent anticoagulation allow provided target INR ≤ 1.5 AND patient stable dose warfarin low molecular weight heparin &gt; 2 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>